v3.25.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Product Liability Contingency [Line Items]      
Net sales  
License agreement description (1) obtain an IND for a patent product within 1 year of the effective date of the agreement, (2) commence a Phase II trial within 2 years of the effective date of the agreement, and (3) submit an NDA or BLA to the FDA or equivalent regulatory agency in another jurisdiction within 7 years of the effective date of the agreement. Pursuant to the Enviro-Cedars License Agreement (Mitochondrial DNA), Enviro is obligated to (1) complete preclinical studies of a patent product within 2 years of the effective date of the agreement, (2) complete toxicology studies within 2.5 years of the effective date of the agreement, (3) obtain IND within 3 years of the effective date of the agreement, (4) begin a Phase I trial within 4 years of the effective date of the agreement, and (5) submit an NDA or BLA to the FDA or equivalent regulatory agency in another jurisdiction within 7 years of the effective date of the agreement. If the Commercialization Milestones are not met or extended, Cedars may convert the exclusive licenses into non-exclusive licenses or to a co-exclusive licenses or terminate the licenses.    
Phase One Clinical Trial [Member]      
Product Liability Contingency [Line Items]      
Payment for milestone $ 150    
Item One And Two [Member]      
Product Liability Contingency [Line Items]      
Payment for milestone 250    
Net sales 5,000    
Item One And Two [Member] | Non-US [Member]      
Product Liability Contingency [Line Items]      
Payment for milestone 1,500    
Item One And Two [Member] | Phase Two [Member]      
Product Liability Contingency [Line Items]      
Payment for milestone 250    
Item Three [Member] | Phase Two Clinical Trial [Member]      
Product Liability Contingency [Line Items]      
Payment for milestone 500    
Item Four [Member]      
Product Liability Contingency [Line Items]      
Payment for milestone 2,500    
Net sales $ 50,000    
Patent product sales 0.50%    
Item Four [Member] | Food and Drug Administration [Member]      
Product Liability Contingency [Line Items]      
Payment for milestone     $ 1,500
Item Four [Member] | Phase Two Clinical Trial [Member]      
Product Liability Contingency [Line Items]      
Payment for milestone $ 250    
License Agreement [Member]      
Product Liability Contingency [Line Items]      
License fee 5    
Annual maintenance fee $ 10    
Exclusive License Agreement [Member]      
Product Liability Contingency [Line Items]      
Royalty percentage 3.75%    
Exclusive License Agreement [Member] | Item Four [Member]      
Product Liability Contingency [Line Items]      
License fee $ 50    
Annual maintenance fee $ 10    
Royalty percentage 4.25%    
Minimum requirerment of capital $ 500    
Exclusive License Agreement [Member] | Minimum [Member]      
Product Liability Contingency [Line Items]      
Patent protection costs $ 9    
Other non-royalty sublicense fees percentage 5.00%    
Exclusive License Agreement [Member] | Minimum [Member] | Item Four [Member]      
Product Liability Contingency [Line Items]      
Other non-royalty sublicense fees percentage 5.00%    
Exclusive License Agreement [Member] | Maximum [Member]      
Product Liability Contingency [Line Items]      
Patent protection costs $ 61    
Other non-royalty sublicense fees percentage 35.00%    
Exclusive License Agreement [Member] | Maximum [Member] | Item Four [Member]      
Product Liability Contingency [Line Items]      
Other non-royalty sublicense fees percentage 35.00%    
Enviro Cedars License Agreements [Member] | Item One And Two [Member] | Phase Three [Member]      
Product Liability Contingency [Line Items]      
Net sales $ 100,000    
Enviro Cedars License Agreements [Member] | Phase Three Clinical Trial [Member]      
Product Liability Contingency [Line Items]      
Net sales $ 50,000